# Nuclide record nct06750419 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct06750419/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct06750419", "NCT06750419" ;
  schema:name "89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study"@en ;
  schema:alternateName "ZIRCON-CP"@en ;
  schema:description "A phase 3 trial of Zirconium-89 girentuximab run by Telix Pharmaceuticals (Innovations) Pty Limited in renal cell carcinoma, now recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct06750419/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06750419> ;
  nuclide:status "recruiting" ;
  nuclide:tag "ctgov-ingest" ;
  nuclide:phase "3" ;
  nuclide:related <https://nuclide.cc/isotopes/zr-89/> ;
  nuclide:indications <https://nuclide.cc/indications/rcc/> ;
  nuclide:drugs <https://nuclide.cc/drugs/girentuximab-zr89/> ;
  nuclide:companies <https://nuclide.cc/companies/telix/> .